Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg lowers target price on Oxford Instruments

(Sharecast News) - Analysts at Berenberg lowered their target price on manufacturing and research firm Oxford Instruments from 2,600.0p to 2,500.0p on Tuesday but noted the group had made a "quantum leap in cash" from self-help efforts. Berenberg noted that Oxford Instruments was transitioning into a more commercially focused organisation, leveraging its "strong technology portfolio" with greater operational efficiency and rigour.

The German bank stated that it views Oxford Instruments' compound semiconductor exposure as "a key driver" of revenue and profit growth in the coming years.

"Following three years of flat operating profits and volatile cash generation, we forecast an inflection in the coming 12 months, said Berenberg. "The valuation is attractive, with scope for a re-rating as cash generation doubles by FY28E."

Bernberg also noted that with a 25% potential upside, it had opted to reiterate its 'buy' rating on the stock, adding that it sees scope for a re-rating as improved financial metrics are delivered.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.